Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.

Abstract

Sunitinib is a tyrosine kinase/angiogenesis inhibitor with proven efficacy in gastrointestinal stromal tumor and advanced renal cell carcinoma. We are presenting the case report of a patient with aggressive alveolar soft part sarcoma with lung and bone metastases, who had failed multiple chemotherapy regimens showing significant response to sunitinib. There was not only complete regression of the primary tumor, stabilization of his bone metastases and significant improvement in the quality of life. Our report shows that sunitinib has the capability of playing a pivotal role in the management of non-gastrointestinal stromal tumors like alveolar soft part sarcoma. Further research and trials must be encouraged over the use of this drug as it is most definitely promising.

• Authors: Abhimanyu Ghose, Zeeshan Tariq, Salvatore Veltri
• Journal: American journal of therapeutics (Am J Ther) Vol. 19 Issue 1 Pg. e56-8 (Jan 2012) ISSN: 1536-3686 [Electronic] United States
• PMID: 20634674 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antineoplastic Agents
• Indoles
• Pyrroles
• Sunitinib

Topics

• Adult
• Angiogenesis Inhibitors (pharmacology, therapeutic use)
• Antineoplastic Agents (pharmacology, therapeutic use)
• Bone Neoplasms (drug therapy, metabolism)
• Drug Resistance, Multiple
• Drug Resistance, Neoplasm
• Humans
• Indoles (pharmacology, therapeutic use)
• Lung Neoplasms (drug therapy, secondary)
• Male
• Pyrroles (pharmacology, therapeutic use)
• Quality of Life
• Sarcoma, Alveolar Soft Part (drug therapy, pathology)
• Sunitinib
• Treatment Outcome